Management of acute and chronic HCV infection in persons with HIV coinfection

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages S108-S119

  Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; HCV; HIV; Interferon; NS5A inhibitors.; Polymerase inhibitors; Protease inhibitors

Indexed keywords

ABT 450; ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ASUNAPREVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; EFAVIRENZ; EMTRICITABINE; GRAZOPREVIR; LEDIPASVIR; MK 8742; NONSTRUCTURAL PROTEIN 3; OMBITASVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT;

ACUTE HEPATITIS; ANTIVIRAL THERAPY; ARTICLE; CHRONIC DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; SEROCONVERSION; SEXUAL BEHAVIOR; TREATMENT RESPONSE; ACUTE DISEASE; COINFECTION; COMORBIDITY; DISEASE MANAGEMENT; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN; TRANSMISSION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; COINFECTION; COMORBIDITY; DISEASE MANAGEMENT; DRUG INTERACTIONS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84913546334     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.006     Document Type: Review

References (112)

1. J. van der Helm Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997 Gastroenterology 144 2013 751 760
2. G. Wandeler Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic Clin Infect Dis 55 2012 1408 1416
3. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men - New York City, 2005-2010 MMWR Morb Mortal Wkly Rep 60 2011 945 950
4. M. Laguno Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients AIDS Res Hum Retroviruses 28 2012 1294 1300
5. J.J. van der Helm The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 AIDS 25 2011 1083 1091
6. T. van de Laar Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men Gastroenterology 136 2009 1609 1617
7. I.T. Williams Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006 Arch Intern Med 171 2011 242 248
8. European, A.T.N.A.H.C.I.C.P. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS treatment network (NEAT) consensus conference AIDS 25 2011 399 409
9. H. Masur Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated Guidelines from the centers for disease control and prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America Clin Infect Dis 58 2014 1308 1311
10. K. Deterding Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial Lancet Infect Dis 13 2013 497 506
11. D.L. Thomas Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
12. M.S. Sulkowski Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
13. S. Naggie, and M.S. Sulkowski Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals Gastroenterology 142 2012 1324 1334
14. G.D. Kirk HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study Ann Intern Med 158 2013 658 666
15. K.N. Ly The increasing burden of mortality from viral hepatitis in the united states between 1999 and 2007 Ann Intern Med 156 2012 271 278
16. B.N. Limketkai Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV JAMA 308 2012 370 378
17. A. Balagopal Human immunodeficiency virus-related microbial translocation and progression of hepatitis C Gastroenterology 135 2008 226 233
18. A. Balagopal Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients Hepatology 60 2014 477 486
19. J. Rohrbach Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals Antivir Ther 19 2014 149 159
20. J. Rohrbach Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy Gut 59 2010 1252 1258
21. N. Qurishi Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection Lancet 362 2004 1708 1713
22. S. Verma Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 42 2006 262 270
23. Adolescents, P.o.O.I.i.H.I.V.I.A.a., Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America; 2103: R-1-R-17.
24. M.A. Thompson Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel JAMA 308 2012 387 402
25. F.J. Torriani Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
26. R.T. Chung Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
27. M. Rodriguez-Torres Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial HIV Clin Trials 13 2012 142 152
28. S.H. Mehta Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic AIDS 20 2006 2361 2369
29. J.R. Kramer Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
30. M.S. Sulkowski Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C Nat Rev Gastroenterol Hepatol 8 2011 212 223
31. R.T. Chung Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
32. S. Mauss Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy AIDS 18 2004 F21 F25
33. M. Sulkowski Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Lancet Infect Dis 13 2013 597 605
34. M.S. Sulkowski Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial Ann Intern Med 2013 10 159
35. M.S. Sulkowski Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
36. A. Osinusi Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV J Hepatol 60 2014 S7
37. M. Sulkowski Efficacy and safety of the all-oral regimen, MK-5172/MK-8742 +/- ribavirin for 12 weeks in GT1 HCV/HIV coinfected patients: the C-WORTHY study J Hepatol 60 2014 S26
38. Rodriguez-Torres M et al. Sofosbuvir and Peginterferon alfa-2a/Ribavirin forTreatment-Naïve Genotype 1-4 HCV Infected Patients who are HIV Coinfected with HIV. ID Week 2013, San Francisco, CA, October 2-6, 2013; abstract 714.
39. Dieterich, DT et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study. 14th European AIDs Conference (EACS 2013). Brussels, October 16-19, 2013; abstract PS9/5.
40. C. Sarrazin Antiviral strategies in hepatitis C virus infection J Hepatol 56 2012 S88 S100
41. G.A. Hardy Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression Blood 113 2009 5497 5505
42. I.M. Jacobson Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
43. F. Poordad Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
44. G.R. Foster Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 881 889
45. T.L. Kieffer Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639
46. I.M. Jacobson Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
47. M. Manns Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
48. F. Poordad Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
49. V. Summa MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
50. J. Guedj Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci U S A 110 2013 3991 3996
51. M. Gao Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
52. A.S. Lok Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
53. N. Afdhal Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
54. N. Afdhal Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
55. K.V. Kowdley Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
56. K.V. Kowdley Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
57. S. Zeuzem Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
58. J.J. Feld Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
59. F. Poordad ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
60. P. Ferenci ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
61. A.M. Lam Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus Antimicrob Agents Chemother 56 2012 3359 3368
62. E. Lawitz Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
63. E.J. Gane Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
64. I.M. Jacobson Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
65. R. Bartenschlager, V. Lohmann, and F. Penin The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat Rev Microbiol 11 2013 482 496
66. I. Gentile, A.R. Buonomo, and G. Borgia Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection Rev Recent Clin Trials 2014 [Epub ahead of print]
67. K.D. Sims Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection Antimicrob Agents Chemother 58 2014 3496 3503
68. G.T. Everson Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
69. H. Hagan, E.R. Pouget, D.C. Des, and D.C. Des Jarlais A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs J Infect Dis 204 2011 74 83
70. A.S. de Vos Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction 108 2013 1070 1081
71. M.D. Witt Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011 Clin Infect Dis 57 2013 77 84
72. L. Cotte Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men Gastroenterol Clin Biol 33 2009 977 980
73. N. Panneer HIV and HCV infection in the United States: whom and how to test Clin Infect Dis 59 2014 875 882
74. D.L. Thomas The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA 284 2000 450 456
75. V. Soriano Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe J Infect Dis 198 2008 1337 1344
76. S.H. Mehta Protection against persistence of hepatitis C Lancet 359 2002 1478 1483
77. S. Beinhardt A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection J Hepatol 59 2013 972 977
78. A. Mangia Treatment optimization and prediction of HCV clearance in patients with acute HCV infection J Hepatol 59 2013 221 228
79. C. Bunchorntavakul Distinct features in natural history and outcomes of acute hepatitis C J Clin Gastroenterol 2014
80. C. Boesecke, and J.K. Rockstroh Treatment of acute hepatitis C infection in HIV-infected patients Curr Opin HIV AIDS 6 2011 278 284
81. G.J. Dore Effective treatment of injecting drug users with recently acquired hepatitis C virus infection Gastroenterology 138 2010 123 135
82. K.E. Corey Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis J Viral Hepat 17 2010 201 207
83. J. Grebely Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine Lancet Infect Dis 12 2012 408 414
84. P. Vickerman The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design J Infect Dis 205 2012 1342 1350
85. F. Carrat Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients - A randomized controlled trial JAMA 292 2004 2839 2848
86. A. Moreno High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin Antivir Ther 9 2004 133 138
87. S.J. Hadziyannis Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
88. M.E. Eyster Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease Blood 84 1994 1020 1023
89. J.J. Kiser Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
90. Poizot-Martin I, Bellissant E, Colson P, et al., and the ANRS-HC27 BOCEPREVIH Study Group. ANRS-HC27 Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; abstract 659LB.
91. B.R. Bacon Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
92. Cotte L, Braun J, Vincent C, Sogni P, et al. Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH). 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014; abstract 668.
93. J.G. McHutchison Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
94. S. Zeuzem Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
95. German P, Pang P, West S, Han L, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 19-21 May 2014, Washington, DC; abstract O-06.
96. M. Bifano Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir Antivir Ther 18 2013 931 940
97. C. Herzode Safety and efficacy of the all-oral regimen of MK-5172/MK-8742 +/- ribavirin in treatment-naïve, non-cirrhotic, patients with hepatitis C genotype 1 infection: the C-WOTHY study J Hepatol 60 2014 S5
98. R.P. van Heeswijk Review of drug interactions with telaprevir and antiretrovirals Antivir Ther 18 2013 553 560
99. K. Seden, D. Back, and S. Khoo Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable J Antimicrob Chemother 64 2009 5 8
100. K.J. Wilby A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients Ann Hepatol 11 2012 179 185
101. E.D. Deeks Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection Drugs 74 2014 195 206
102. T. Asselah ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection J Hepatol 59 2013 885 888
103. W.N. Schmidt Direct acting antiviral agents and the path to interferon independence Clin Gastroenterol Hepatol 12 5 2014 728 737
104. D.L. Thomas Hepatitis C in HIV-infected individuals: cure and control, right now J Int AIDS Soc 14 2011 22
105. D. Alvarez Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons J Viral Hepat 13 2006 683 689
106. G. Visco Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis Gut 34 1993 S107 S108
107. J. Balzarini Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus J Biol Chem 266 1991 21509 21514
108. R. Fleischer, D. Boxwell, and K.E. Sherman Nucleoside analogues and mitochondrial toxicity Clin Infect Dis 38 2004 e79 e80
109. Sovaldi™ (sofosbuvir) tablets prescribing information. Gilead Sciences, Inc., Foster City, CA 2013.
110. E.G. Hulskotte Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir Clin Infect Dis 56 2013 718 726
111. Olysio™ (simeprevir) capsules prescribing information. Janssen Therapeutics, Titusville, NJ 2013.
112. V. Garg The Effect of CYP3A Inhibitors and Inducers on the Pharmacokinetics of Telaprevir in Healthy Volunteers Br J Clin Pharmacol 75 2013 431 439